Cargando…

How to choose initial treatment in multiple sclerosis patients: a case-based approach

BACKGROUND: Immunotherapy dramatically changed the natural history of multiple sclerosis (MS), which was classically associated with severe disability. Treatment strategies advocate that early control of disease activity is crucial to avoid progressive disability, and the use of high efficacy drugs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Apóstolos, Samira Luisa Pereira, Boaventura, Mateus, Mendes, Natalia Trombini, Teixeira, Larissa Silva, Campana, Igor Gusmão
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academia Brasileira de Neurologia - ABNEURO 2022
Materias:	Inflammatory and Demyelinating Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491420/ https://www.ncbi.nlm.nih.gov/pubmed/35976318 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S128

Ejemplares similares

A critical review and update on autoimmune encephalitis: understanding the alphabet soup
por: Simabukuro, Mateus Mistieri, et al.
Publicado: (2022)

Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review
por: Silva, Guilherme Diogo, et al.
Publicado: (2022)

Differential diagnosis of demyelinating diseases: what's new?
por: Gomes, Ana Beatriz Ayroza Galvão Ribeiro, et al.
Publicado: (2022)

Quality of Life in Multiple Sclerosis
por: Williams, Mitchell T., et al.
Publicado: (2020)

Axonal Damage in Pediatric Multiple Sclerosis
por: Kuntz, Nancy L.
Publicado: (2015)

MRI to Discriminate Pediatric MS from ADEM
por: Rubin, Jennifer P.
Publicado: (2015)

Relation of Posterior Cerebellar Volume to Cognition in MS
por: Millichap, J. Gordon
Publicado: (2015)

Prognostic Factors of MS Conversion in Optic Neuritis
por: Fajardo, Marytery, et al.
Publicado: (2015)

Plasma Exchange for Treatment of Refractory Demyelination
por: Cronin, Michael, et al.
Publicado: (2020)

Similar geographic distributions of death rates from inflammatory bowel disease and Hodgkin lymphoma or multiple sclerosis
por: Sonnenberg, Amnon
Publicado: (2023)

Beyond borders: Do geographic correlations suggest shared environmental factors in inflammatory bowel diseases, Hodgkin lymphoma, and multiple sclerosis
por: Fay, Shmuel, et al.
Publicado: (2023)

Reporting of endoscopy and histology of ulcerative colitis in routine clinical practice: How far we are!
por: Magro, Fernando, et al.
Publicado: (2023)

Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
por: Stournaras, Evangelos, et al.
Publicado: (2021)

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
por: Magro, Fernando, et al.
Publicado: (2023)

Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale
por: Adegbola, Samuel O, et al.
Publicado: (2021)

Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772)
por: Sheridan, Juliette, et al.
Publicado: (2018)

Peripheral blood lymphopenia in sarcoidosis associates with HLA-DRB1 alleles but not with lung immune cells and organ involvement
por: Darlington, Pernilla, et al.
Publicado: (2023)

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
por: Mayer, Lloyd, et al.
Publicado: (2014)

Variables associated with progression of moderate-to-severe Crohn’s disease
por: Sacramento, Carolina da Silva Beda, et al.
Publicado: (2022)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

A microbial signature for Crohn's disease
por: Pascal, Victoria, et al.
Publicado: (2017)

Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important?
por: Oset, Magdalena, et al.
Publicado: (2020)

Faster and less invasive tools to identify patients with ileal colonization by adherent‐invasive E. coli in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse
por: Arrieta, M C, et al.
Publicado: (2008)

Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition
por: Binion, D G, et al.
Publicado: (2008)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis
por: Aherne, Carol M, et al.
Publicado: (2011)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
por: Kruis, W, et al.
Publicado: (2009)

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion
por: Rolhion, Nathalie, et al.
Publicado: (2010)

Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers
por: Roberts, Carol L, et al.
Publicado: (2010)

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ct7i2cntp90jr3lk83ebnnnvof